Explore the words cloud of the TRACE project. It provides you a very rough idea of what is the project "TRACE" about.
The following table provides information about the project.
Coordinator |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address contact info |
Coordinator Country | Germany [DE] |
Project website | http://www.trace-study.de |
Total cost | 6˙000˙000 € |
EC max contribution | 6˙000˙000 € (100%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-SC1-2017-Two-Stage-RTD |
Funding Scheme | RIA |
Starting year | 2018 |
Duration (year-month-day) | from 2018-01-01 to 2022-12-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | DE (MUENCHEN) | coordinator | 1˙641˙600.00 |
2 | ORION CLINICAL SERVICES LTD | UK (SLOUGH) | participant | 2˙099˙005.00 |
3 | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY | FR (NANCY CEDEX) | participant | 507˙570.00 |
4 | OSPEDALE PEDIATRICO BAMBINO GESU | IT (ROMA) | participant | 442˙025.00 |
5 | Universitair Ziekenhuis Gent | BE (Gent) | participant | 401˙550.00 |
6 | ACADEMISCH ZIEKENHUIS LEIDEN | NL (LEIDEN) | participant | 350˙600.00 |
7 | UNIVERSITY OF NEWCASTLE UPON TYNE | UK (NEWCASTLE UPON TYNE) | participant | 349˙725.00 |
8 | MILTENYI BIOTEC GMBH | DE (BERGISH GLADBACH) | participant | 207˙925.00 |
Allogeneic stem cell transplantation (HSCT) is a curative treatment for a variety of diseases. Viral infections such as Cytomegalovirus (CMV), Epstein-Barr-virus (EBV) and Adenovirus (AdV) are major unsolved problems for patients receiving allogeneic HSCT. Refractory viral infections post-HSCT are rare, life-threatening conditions due to the deficient T-cell response post-SCT and lacking effective treatment options. Protective T-cell immunity could be restored by means of a procedure known as adoptive T-cell transfer. Although cellular immunotherapy is considered a major recent breakthrough in medicine, none of the cellular treatment approaches has yet become a standard treatment. The reason for this limited translation into daily clinical practice is the lack of controlled, prospective clinical trials investigating efficacy of immunotherapy. The objective of TRACE is to bring adoptive T-cell transfer into clinical routine as a life-saving, curative and safe treatment for refractory viral infection post-HSCT. TRACE is a multi-national clinical trial to prove efficacy and safety of adoptive T-cell transfer in immune-compromized individuals. For the first time, this trial will show that a unique individualized immunotherapy could be included into evidence based clinical routine in rare diseases. Regulatory and structural hurdles will be overcome by standardized GMP-procedures. It will be a major milestone in the development of medicine and health economics to bring such a unique personalized treatment approach into a clinical efficacy trial. The consortium provide excellence in immunotherapy through partners from basic, clinical and industrial research and GMP facilities, with proven qualification and expertise in the field of HSCT, GMP manufacturing and adoptive T-cell transfer. It will bring medicine towards physiological self-protection of the human body instead of cost-intensive toxic agents and will thereby improve survival and quality of life.
Individualized press release for every partner | Documents, reports | 2020-04-07 22:49:03 |
Registration number of clinical study in a WHO- or ICMJE-approved registry | Documents, reports | 2020-04-07 22:49:03 |
Final version of study protocol as approved by first regulatory/ethics committee (Package 1) | Documents, reports | 2020-04-07 22:49:03 |
Launch of website and social media account | Websites, patent fillings, videos etc. | 2020-04-07 22:49:03 |
Plan for the analysis of the functional activity of the multivirus-specific T cell product | Documents, reports | 2020-04-07 22:49:03 |
SOP for immune monitoring of patient samples | Documents, reports | 2020-04-07 22:49:03 |
Site selection | Documents, reports | 2020-04-07 22:49:03 |
Take a look to the deliverables list in detail: detailed list of TRACE deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2019 |
Theresa Kaeuferle, Ramona Krauss, Franziska Blaeschke, Semjon Willier, Tobias Feuchtinger Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation published pages: 12-13, ISSN: 1756-8722, DOI: 10.1186/s13045-019-0701-1 |
Journal of Hematology & Oncology 12/1 | 2020-04-07 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRACE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TRACE" are provided by the European Opendata Portal: CORDIS opendata.